The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

D. S. Goodin, B. G. Arnason, P. K. Coyle, Elliot Frohman, D. W. Paty

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers use of mitoxantrone in the treatment of MS. Mitoxantrone probably reduces the clinical attack rate and reduces attack-related MRI outcomes in patients with relapsing MS (Type B recommendation). Also, mitoxantrone may have a beneficial effect on disease progression in patients with MS whose clinical condition is worsening (Type B recommendation). The potential for serious toxicity of mitoxantrone, however, must be taken into account when considering this therapy in individual patients. Moreover, because the potential clinical benefits on disease progression appear to be only modest, the results of the single phase III trial should be replicated in another (and hopefully much larger) clinical study before this agent is widely recommended for the treatment of patients with MS.

Original languageEnglish (US)
Pages (from-to)1332-1338
Number of pages7
JournalNeurology
Volume61
Issue number10
StatePublished - Nov 25 2003

Fingerprint

Biomedical Technology Assessment
Mitoxantrone
Multiple Sclerosis
Disease Progression
Chronic Progressive Multiple Sclerosis
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. / Goodin, D. S.; Arnason, B. G.; Coyle, P. K.; Frohman, Elliot; Paty, D. W.

In: Neurology, Vol. 61, No. 10, 25.11.2003, p. 1332-1338.

Research output: Contribution to journalArticle

@article{8066b7e7568e4dd7bda582eb8dbe7644,
title = "The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology",
abstract = "Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers use of mitoxantrone in the treatment of MS. Mitoxantrone probably reduces the clinical attack rate and reduces attack-related MRI outcomes in patients with relapsing MS (Type B recommendation). Also, mitoxantrone may have a beneficial effect on disease progression in patients with MS whose clinical condition is worsening (Type B recommendation). The potential for serious toxicity of mitoxantrone, however, must be taken into account when considering this therapy in individual patients. Moreover, because the potential clinical benefits on disease progression appear to be only modest, the results of the single phase III trial should be replicated in another (and hopefully much larger) clinical study before this agent is widely recommended for the treatment of patients with MS.",
author = "Goodin, {D. S.} and Arnason, {B. G.} and Coyle, {P. K.} and Elliot Frohman and Paty, {D. W.}",
year = "2003",
month = "11",
day = "25",
language = "English (US)",
volume = "61",
pages = "1332--1338",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis

T2 - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

AU - Goodin, D. S.

AU - Arnason, B. G.

AU - Coyle, P. K.

AU - Frohman, Elliot

AU - Paty, D. W.

PY - 2003/11/25

Y1 - 2003/11/25

N2 - Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers use of mitoxantrone in the treatment of MS. Mitoxantrone probably reduces the clinical attack rate and reduces attack-related MRI outcomes in patients with relapsing MS (Type B recommendation). Also, mitoxantrone may have a beneficial effect on disease progression in patients with MS whose clinical condition is worsening (Type B recommendation). The potential for serious toxicity of mitoxantrone, however, must be taken into account when considering this therapy in individual patients. Moreover, because the potential clinical benefits on disease progression appear to be only modest, the results of the single phase III trial should be replicated in another (and hopefully much larger) clinical study before this agent is widely recommended for the treatment of patients with MS.

AB - Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers use of mitoxantrone in the treatment of MS. Mitoxantrone probably reduces the clinical attack rate and reduces attack-related MRI outcomes in patients with relapsing MS (Type B recommendation). Also, mitoxantrone may have a beneficial effect on disease progression in patients with MS whose clinical condition is worsening (Type B recommendation). The potential for serious toxicity of mitoxantrone, however, must be taken into account when considering this therapy in individual patients. Moreover, because the potential clinical benefits on disease progression appear to be only modest, the results of the single phase III trial should be replicated in another (and hopefully much larger) clinical study before this agent is widely recommended for the treatment of patients with MS.

UR - http://www.scopus.com/inward/record.url?scp=0345305703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345305703&partnerID=8YFLogxK

M3 - Article

C2 - 14638950

AN - SCOPUS:0345305703

VL - 61

SP - 1332

EP - 1338

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -